TC BioPharm (Holdings) plc (TCBP)
Market Cap | 26.80M |
Revenue (ttm) | 2.73M |
Net Income (ttm) | -5.17M |
Shares Out | 28.06M |
EPS (ttm) | -0.18 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 176,367 |
Open | 0.990 |
Previous Close | 0.953 |
Day's Range | 0.901 - 1.040 |
52-Week Range | 0.880 - 3.500 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About TCBP
TCB is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled TCB to develop a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. TCB is embarking on phase II-into-pivotal (phase III) clinical studies, which are expected to commence in the fourth quarter of 2021, following United Kingdom and European Union regulati... [Read more...]
Financial Performance
In 2020, TCBP's revenue was 1.98 million, a decrease of -42.26% compared to the previous year's 3.43 million. Losses were -5.46 million, -10.05% less than in 2019.
Financial numbers in millions GBPFinancial StatementsNews

TC BioPharm Invited to Present at LD Micro Conference
EDINBURGH, Scotland , May 3, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform a...

TC BioPharm to Participate in Upcoming Conferences
EDINBURGH, Scotland , April 26, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day
EDINBURGH, Scotland , April 21, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process
6-month shelf-life milestone achieved Successful thaw of highly activated Gamma delta cells EDINBURGH, Scotland , April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company"...

TC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" Recommendation
EDINBURGH, Scotland , March 29, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Trea...
Trial enrollment expected to begin during the first half of 2022 EDINBURGH, Scotland , March 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: ...
Why Are TC Biopharm Shares Trading Higher Today
The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ: TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia. After reviewing the Phase 1b/2a trial results in relapsed/refra...

TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune®
Allogeneic unmodified Gamma Delta product can be stored frozen and used as an 'off-the-shelf' cell therapy EDINBURGH, Scotland , March 17, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" ...

TC Biopharm Updates Intellectual Property Portfolio
EDINBURGH, Scotland, March 15, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform...

Newly-Listed TC Biopharm Highlights Early Data From Acute Myeloid Leukemia Trial
TC Biopharm Ltd (NASDAQ: TCBP) has announced interim data from Phase 1a/2b of TCB-002, OmnImmune in relapsed/refractory Acute Myeloid Leukemia (AML). TCB-002 is the Company's allogeneic unmodified gamm...

TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic...
EDINBURGH, Scotland, March 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...

TC Biopharm to Host Corporate Update Call on March 8th
EDINBURGH, Scotland, March 2, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...

TC Biopharm Announces Appointment of New Board Members
EDINBURGH, Scotland, Feb. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...

TC Biopharm Announces Closing of $17.5 Million Initial Public Offering
EDINBURGH, Scotland, Feb. 15, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform ...

Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February
Here's three penny stocks that investors are watching rig The post Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...

5 ‘Must Watch' Penny Stocks For February 2022
5 must watch penny stocks that you should know about in February The post 5 ‘Must Watch' Penny Stocks For February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

TC BioPharm Begins Trading on Nasdaq Today Under Symbol "TCBP"
EDINBURGH, Scotland, Feb. 11, 2022 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for canc...